MAPT and Alzheimer disease: Over 200 anti-AD drugs targeting Aβ and tau therapies have undergone clinical trials, but only a few have received approval from the Food and Drug Administration (FDA) with considerable controversy [4], highlighting the need for a better understanding of the pathological mechanism of AD.